Eli Lilly exhibits robust revenue growth, with Q2 revenue surging by 36%, driven by new products contributing nearly $3.5 billion compared to the same period last year (David Ricks, Chair and CEO).

Eli Lilly has slashed the prices of starter doses of Zepbound to “significantly” expand the supply of the popular weight loss drug amid high demand in the United States. Single-dose vials ...

Eli Lilly and Company’s LLY stock has risen 21.1% in six months compared with an increase of 10.5% for the industry. The stock has also outperformed the sector as well as the S&P 500 as seen in ...

Eli Lilly has been rolling out Zepbound in recent months, and demand has been "unbelievable," says the CEO. Sales have been taking off, and that's even without spending aggressively on sales and ...

Eli Lilly is investing $1.8 billion to expand production in Ireland of its Alzheimer's treatment and weight-loss drugs. The company's Alzheimer's drug, Kisunla, was approved by the U.S. Food and ...

How Eli Lilly’s Next 5 Years Could Play Out We expect Eli Lilly’s P/E ratio in 2025 to be 60 with an EPS of $19.11, resulting in a price target of $1140.00 This prediction is based on strong ...

The low doses are also available with an auto-injector pen, but at a higher price than the vials. Eli Lilly said this new product will help with supply chain issues and increase access for those ...

Eli Lilly (LLY) Stock Price Prediction in 2025 The current Wall Street consensus 1-year target of Eli Lilly stock is $898, which is 3.96% lower than today’s price of $935.06. Of the 26 analysts ...

Eli Lilly (NYSE: LLY) offers investors the same thing as many other big pharma companies: a certain level of security when it comes to revenue. Since people need their medicines regardless of the ...

Eli Lilly is ramping up its campaign against imitations of its blockbuster appetite-suppressing drugs, seeking to put an end to a regulatory designation that has allowed cheaper, off-brand ...

Eli Lilly reduces price of weight loss medicine Zepbound, offering discounts to patients. Obesity rates skyrocket in America.

Eli Lilly is expanding the supply of its weight-loss drug and selling it for half the price of other drugs in the highly lucrative market. Eli Lilly announced on Tuesday that it is now offering ...